Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 4.77
BIOC's Cash-to-Debt is ranked lower than
60% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. BIOC: 4.77 )
Ranked among companies with meaningful Cash-to-Debt only.
BIOC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.86 Max: No Debt
Current: 4.77
Equity-to-Asset 0.58
BIOC's Equity-to-Asset is ranked lower than
89% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIOC: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
BIOC' s Equity-to-Asset Range Over the Past 10 Years
Min: -18.63  Med: 0.09 Max: 0.83
Current: 0.58
-18.63
0.83
Piotroski F-Score: 5
Altman Z-Score: -12.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -376.52
BIOC's Operating Margin % is ranked lower than
90% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. BIOC: -376.52 )
Ranked among companies with meaningful Operating Margin % only.
BIOC' s Operating Margin % Range Over the Past 10 Years
Min: -1227100  Med: -7782.07 Max: -376.52
Current: -376.52
-1227100
-376.52
Net Margin % -383.29
BIOC's Net Margin % is ranked lower than
90% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. BIOC: -383.29 )
Ranked among companies with meaningful Net Margin % only.
BIOC' s Net Margin % Range Over the Past 10 Years
Min: -1362900  Med: -9069.01 Max: -383.29
Current: -383.29
-1362900
-383.29
ROE % -1599.59
BIOC's ROE % is ranked lower than
99.99% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. BIOC: -1599.59 )
Ranked among companies with meaningful ROE % only.
BIOC' s ROE % Range Over the Past 10 Years
Min: -1599.59  Med: -910.96 Max: -845.54
Current: -1599.59
-1599.59
-845.54
ROA % -214.40
BIOC's ROA % is ranked lower than
96% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. BIOC: -214.40 )
Ranked among companies with meaningful ROA % only.
BIOC' s ROA % Range Over the Past 10 Years
Min: -694.81  Med: -530.13 Max: -197.38
Current: -214.4
-694.81
-197.38
ROC (Joel Greenblatt) % -1134.96
BIOC's ROC (Joel Greenblatt) % is ranked lower than
90% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. BIOC: -1134.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIOC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2717.73  Med: -1382.83 Max: -1134.96
Current: -1134.96
-2717.73
-1134.96
3-Year Revenue Growth Rate 55.90
BIOC's 3-Year Revenue Growth Rate is ranked higher than
95% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. BIOC: 55.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIOC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.4 Max: 55.9
Current: 55.9
0
55.9
3-Year EBITDA Growth Rate -26.10
BIOC's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. BIOC: -26.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIOC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -36.9 Max: -26.1
Current: -26.1
GuruFocus has detected 1 Warning Sign with Biocept Inc $BIOC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIOC's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:OTCPK:PRFMF, NAS:HTGM, OTCBB:INIS, NAS:SLNO, NAS:CHEK, OTCPK:SEOVF, AMEX:PTN, NAS:CDNA, NAS:DRIO, NAS:TROV, NAS:BIOP, OTCPK:LXXGF, NAS:OPGN, OTCPK:TDSGF, OTCPK:SQIDF, NAS:GENE, OTCPK:MYAN, NAS:CBMX, NAS:IDXG, OTCPK:MHTX » details
Traded in other countries:B001.Germany,
Headquarter Location:USA
Biocept Inc is a cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.

Ratios

vs
industry
vs
history
PB Ratio 3.23
BIOC's PB Ratio is ranked lower than
99% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. BIOC: 3.23 )
Ranked among companies with meaningful PB Ratio only.
BIOC' s PB Ratio Range Over the Past 10 Years
Min: 2.09  Med: 4.33 Max: 62.37
Current: 3.23
2.09
62.37
PS Ratio 4.14
BIOC's PS Ratio is ranked lower than
65% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. BIOC: 4.14 )
Ranked among companies with meaningful PS Ratio only.
BIOC' s PS Ratio Range Over the Past 10 Years
Min: 2.45  Med: 34.72 Max: 195.69
Current: 4.14
2.45
195.69
EV-to-EBIT -1.65
BIOC's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. BIOC: -1.65 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOC' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.2  Med: -1.1 Max: -0.1
Current: -1.65
-3.2
-0.1
EV-to-EBITDA -1.69
BIOC's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. BIOC: -1.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.3  Med: -1.1 Max: -0.1
Current: -1.69
-3.3
-0.1
Current Ratio 2.90
BIOC's Current Ratio is ranked lower than
81% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BIOC: 2.90 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.89 Max: 10.2
Current: 2.9
0.02
10.2
Quick Ratio 2.80
BIOC's Quick Ratio is ranked lower than
77% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. BIOC: 2.80 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.78 Max: 10.09
Current: 2.8
0.02
10.09
Days Inventory 23.48
BIOC's Days Inventory is ranked higher than
74% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. BIOC: 23.48 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s Days Inventory Range Over the Past 10 Years
Min: 9.26  Med: 21.36 Max: 23.71
Current: 23.48
9.26
23.71
Days Sales Outstanding 65.05
BIOC's Days Sales Outstanding is ranked higher than
97% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. BIOC: 65.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.61  Med: 27.35 Max: 1825
Current: 65.05
14.61
1825
Days Payable 69.49
BIOC's Days Payable is ranked lower than
53% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. BIOC: 69.49 )
Ranked among companies with meaningful Days Payable only.
BIOC' s Days Payable Range Over the Past 10 Years
Min: 50.27  Med: 174.59 Max: 22179.12
Current: 69.49
50.27
22179.12

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -126.50
BIOC's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. BIOC: -126.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -126.5  Med: -99 Max: 0
Current: -126.5
-126.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.20
BIOC's Price-to-Net-Cash is ranked lower than
99.99% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. BIOC: 5.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BIOC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.99  Med: 4.93 Max: 14.28
Current: 5.2
2.99
14.28
Price-to-Net-Current-Asset-Value 4.08
BIOC's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. BIOC: 4.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIOC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.75  Med: 4.4 Max: 9.86
Current: 4.08
2.75
9.86
Price-to-Tangible-Book 3.23
BIOC's Price-to-Tangible-Book is ranked lower than
98% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. BIOC: 3.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIOC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.63  Med: 4.31 Max: 20.53
Current: 3.23
2.63
20.53
Price-to-Median-PS-Value 0.12
BIOC's Price-to-Median-PS-Value is ranked higher than
95% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BIOC: 0.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1.02 Max: 3.24
Current: 0.12
0.07
3.24
Earnings Yield (Greenblatt) % -60.61
BIOC's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. BIOC: -60.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -67.14  Med: 0 Max: 0
Current: -60.61
-67.14
0

More Statistics

Revenue (TTM) (Mil) $4.69
EPS (TTM) $ -1.42
Beta3.00
Short Percentage of Float19.90%
52-Week Range $0.74 - 3.39
Shares Outstanding (Mil)26.60

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 6 9
EPS ($) -0.81 -0.70
EPS without NRI ($) -0.81 -0.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Sol May 22 2017 
Biocept Reports First Quarter 2017 Financial Results May 11 2017 
The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landm May 10 2017 
Biocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, May 03 2017 
Biocept Awarded Additional Patent in Japan Expanding Intellectual Property Estate to 19 Issued Paten Apr 18 2017 
Biocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption Apr 03 2017 
Biocept to Present at The MicroCap Conference on April 4th in New York City Mar 31 2017 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Today's Research Reports on Stocks to Watch: Radius Health and Biocept Inc. May 23 2017
Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any... May 22 2017
Vaccine may cut HPV infections, an oral cancer risk, in men May 18 2017
Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society... May 18 2017
Today's Research Reports on Stocks to Watch: Biocept and Hornbeck Offshore Services May 15 2017
ETFs with exposure to Biocept, Inc. : May 12, 2017 May 12 2017
Biocept Reports First Quarter 2017 Financial Results May 11 2017
Investor Network: Biocept, Inc. to Host Earnings Call May 11 2017
The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of... May 10 2017
Biocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11,... May 03 2017
GSK warns of impact from generic drugs after solid Q1 Apr 26 2017
$3M award in suit against drug company over man's suicide Apr 20 2017
ETFs with exposure to Biocept, Inc. : April 20, 2017 Apr 20 2017
Biocept Awarded Additional Patent in Japan Expanding Intellectual Property Estate to 19 Issued... Apr 18 2017
FDA pick faces questioning on ties to industry he'd regulate Apr 05 2017
Biocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption... Apr 03 2017
Biocept to Present at The MicroCap Conference on April 4th in New York City Mar 31 2017
Biocept, Inc. :BIOC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)